Callos Andrew, EVP and Chief Commercial Officer, has demonstrated a consistent pattern of selling shares in Cytokinetics (CYTK) over recent months, with no recent purchases recorded. Since January 2026, Andrew has executed 14 sales totaling over $5.8 million, including high-value transactions such as a $928,050 sale on March 5 and a $904,200 sale on January 5. Smaller but repeated sales—such as those on March 17 ($181,229 and $349,656) and March 31 ($236,535)—further reinforce the trend. The transactions often coincide with option exercises (coded "M"), where shares acquired at lower strike prices were subsequently sold at market value, as seen in multiple instances where $348,900 in option awards preceded sales in the hundreds of thousands.
Andrew’s trading history shows a long-term net disposition of CYTK shares, with total sales exceeding $8.5 million against $3.4 million in buys across 37 filings. The recent activity, entirely concentrated on selling, suggests a continued reduction in his equity position. While some sales appear routine—such as those tied to scheduled option exercises—the frequency and size of disposals, particularly in Q1 2026, indicate a deliberate unwinding of holdings. The absence of any buys during this period contrasts with earlier activity, underscoring a shift toward liquidity over accumulation in his dealings with Cytokinetics stock.
AI-assisted summary